208 related articles for article (PubMed ID: 29091481)
1. The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
Moon JY; Franchi F; Rollini F; Angiolillo DJ
Expert Rev Hematol; 2018 Jan; 11(1):5-12. PubMed ID: 29091481
[TBL] [Abstract][Full Text] [Related]
2. Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
Welsh RC; Peterson ED; De Caterina R; Bode C; Gersh B; Eikelboom JW
Am Heart J; 2019 Dec; 218():100-109. PubMed ID: 31715433
[TBL] [Abstract][Full Text] [Related]
3. Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients.
Sabouret P; Savage MP; Fischman D; Costa F
Am J Cardiovasc Drugs; 2021 Jan; 21(1):21-34. PubMed ID: 32394296
[TBL] [Abstract][Full Text] [Related]
4. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Thompson PL; Verheugt FW
Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549
[TBL] [Abstract][Full Text] [Related]
5. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
Paravattil B; Elewa H
J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
[TBL] [Abstract][Full Text] [Related]
7. Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation.
Chen H; Power D; Giustino G
Expert Rev Cardiovasc Ther; 2018 Oct; 16(10):735-748. PubMed ID: 30221557
[TBL] [Abstract][Full Text] [Related]
8. Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists.
Bailey AL; Campbell CL
Curr Drug Targets; 2011 Nov; 12(12):1805-12. PubMed ID: 21718239
[TBL] [Abstract][Full Text] [Related]
9. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
[TBL] [Abstract][Full Text] [Related]
10. Omitting aspirin in PCI patients: Myth or reality?
Alexopoulos D; Mpahara A; Kassimis G
Cardiovasc Drugs Ther; 2019 Dec; 33(6):711-724. PubMed ID: 31811419
[TBL] [Abstract][Full Text] [Related]
11. Bleeding versus thrombosis: role of short DAPT in complex lesions.
Calcagno S; Lucisano L; Mancone M; Cavallo E; Pennacchi M; Stio RE; Sardella G
Minerva Cardioangiol; 2015 Dec; 63(6):533-46. PubMed ID: 26334115
[TBL] [Abstract][Full Text] [Related]
12. [Managing antithrombotic therapy in vitreoretinal surgery].
Gallice M; Rouberol F; Albaladejo P; Brillat Zaratzian E; Palombi K; Aptel F; Romanet JP; Chiquet C
J Fr Ophtalmol; 2015 Jan; 38(1):61-73. PubMed ID: 25577431
[TBL] [Abstract][Full Text] [Related]
13. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Parker WA; Storey RF
Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
[TBL] [Abstract][Full Text] [Related]
14. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
Pandit A; Giri S; Hakim FA; Fortuin FD
Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
[TBL] [Abstract][Full Text] [Related]
15. Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28780510
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Pareek M; Bhatt DL; Ten Berg JM; Kristensen SD; Grove EL
Expert Opin Pharmacother; 2017 Jun; 18(9):875-883. PubMed ID: 28489475
[TBL] [Abstract][Full Text] [Related]
17. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
[TBL] [Abstract][Full Text] [Related]
18. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
Cairns JA; McMurtry MS
Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
[TBL] [Abstract][Full Text] [Related]
19. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
20. Modern antiplatelet agents in coronary artery disease.
Power RF; Hynes BG; Moran D; Yagoub H; Kiernan G; Ruggiero NJ; Kiernan TJ
Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1261-72. PubMed ID: 23190065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
